Asymmetic Formal [3+3]-Cycloaddition Reactions of Nitrones

with Electrophilic Vinylcarbene Intermediates

Xiaochen Wang, Xinfang Xu, Peter Y. Zavalij, and Michael P. Doyle*

Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742,

United States

Supporting Information

- S2 General
- S2-8 Procedures and Product Analyses
- S8 References
- S9-21 NMR Spectra
- S22-34 HPLC Analyses

General Information. All reactions, unless noted, were carried out under an inert atmosphere of dried nitrogen in flame-dried or oven-dried glassware with magnetic stirring. Analytical thin layer chromatography (TLC) was performed on Dynamic Adsorbents precoated (0.25 mm thickness) silica gel plates with F_{254} indicator. Visualization was accomplished by UV light (254 nm) or phosphomolybdic acid (PMA) solution in ethanol. Flash chromatography was performed with silica gel (32-63 µm) supplied by Dynamic Adsorbents. ¹H NMR spectra were recorded on a Bruker DRX-400 (400 MHz) spectrometer and chemical shifts were reported in ppm. The peak information was described as: br = broad, s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, comp = composite; coupling constant(s) in Hz. ¹³C NMR spectra were recorded on a Bruker DRX-400 (100 MHz) or a Bruker DRX-500 (125 MHz) spectrometer with complete proton decoupling. Enantioselectivity was determined on an Agilent 1200 Series HPLC using a Daicel Chiralcel OD-H column or an AD-H column. High-resolution mass spectra (HRMS) were performed on JEOL AccuTOF-CS mass spectrometer using CsI as the standard.

Materials. $Rh_2(S-PTA)_4^{1}$, $Rh_2(S-PTV)_4^{1}$, $Rh_2(S-PTTL)_4^{1}$, $Rh_2(S-PTPA)_4^{1}$, $Rh_2(S-NTA)_4^{2}$, and $Rh_2(S-NTTL)_4^{2}$ were prepared according to the literature procedures. $Rh_2(S-PTAD)_4^{3}$ and $Rh_2(S-DOSP)_4^{4}$ were purchased from Strem Chemicals, Inc. Nitrones⁵ and the TBSO-substituted vinyldiazoacetate **5**⁶ were prepared according to the literature procedures. Solvents were dried with 4 Å MS before use. All the other chemicals were obtained from commercial sources and used without further purification.

General Procedure for the Asymmetric Formal [3+3] Cycloaddition Reactions of Nitrones with the TBSO-Substituted Vinyldiazoacetate 5. A 10 mL Schlenk flask charged with a magnetic stir bar and 4 Å molecular sieves (100 mg) was placed under high vacuum and heated by Bunsen burner to dryness. After cooling to room temperature, $Rh_2(S-PTA)_4$ (5.4 mg, 2.0 mol%), *N*,α-diphenylnitrone (49.3 mg, 0.250 mmol) and 1.0 mL of *tert*-butyl methyl ether (TBME) were added under the flow of N₂. The resulting green solution was stirred for 5 min and then cooled to -30 °C. Methyl 3-(*tert*-butyldimethylsilyloxy)-2-diazobut-3-enoate (5, 96 mg, 0.38 mmol) in 1.0 mL of TBME was added into the flask *via* a syringe pump over a time period of 1 h. After the addition, the mixture was stirred for another one hour at -30 °C. The reaction mixture was then allowed to warm to room temperature. The solution was evaporated to dryness. The obtained mixture was dissolved in a minimal amount of dichloromethane and loaded onto a silica gel column. Column chromatography with hexane/ethyl acetate provided the cycloaddition product which was later analyzed for enantiomeric excess by HPLC (AD-H or OD-H column).



Methyl 5-(*tert*-Butyldimethylsilyloxy)-2,3-diphenyl-3,6-dihydro-2*H*-1,2-oxazine-4carboxylate (11a). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.19-7.26 (comp, 7H), 7.01 (d, J = 8.0 Hz, 2H), 6.95 (t, J = 7.2 Hz, 1H), 5.61 (d, J = 1.6 Hz, 1H), 4.51 (dd, J = 16.0 Hz, 1.6 Hz, 1H), 4.31 (d, J = 16.0 Hz, 1H), 3.67 (s, 3H), 1.01 (s, 9H), 0.27 (s, 3H), 0.23 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ165.79, 158.50, 147.98, 138.00, 129.80, 128.98, 127.95, 122.91, 117.76, 109.69, 68.81, 63.55, 51.66, 26.01, 18.80, -3.58, -3.65; HRMS (ESI) calculated for C₂₄H₃₂NO₄Si [M+H] ⁺: 426.2095; found: 426.2088. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 1.0 mL/min, hexane:IPA = 95:5, t_r = 5.9, 6.6 min; 93% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-2-phenyl-3-*p*-tolyl-3,6-dihydro-2*H*-1,2-oxazine-4carboxylate (11b). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 6.93-7.30 (comp, 9H), 5.61 (d, *J* = 1.6 Hz, 1H), 4.50 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.31 (d, *J* = 16.0 Hz, 1H), 3.68 (s, 3H), 2.28 (s, 3H), 1.02 (s, 9H), 0.28 (s, 3H), 0.21 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.81, 158.33, 148.06, 137.51, 135.05, 129.69, 129.00, 128.76, 122.80, 117.69, 109.93, 68.86, 63.13, 51.66, 26.07, 21.55, 18.83, -3.56, -3.61; HRMS (ESI) calculated for C₂₅H₃₄NO₄Si [M+H] ⁺: 440.2252; found: 440.2233. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 1.0 mL/min, hexane:IPA = 97:3, t_r = 6.1, 8.0 min; 87% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(4-methoxyphenyl)-2-phenyl-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11c). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.19-7.26 (comp, 2H), 7.17 (d, *J* = 8.0 Hz, 2H), 7.01 (d, *J* = 8.0 Hz, 2H), 6.95 (t, *J* = 7.6 Hz, 1H), 6.73 (d, *J* = 8.0 Hz, 2H), 5.57 (d, *J* = 1.6 Hz, 1H), 4.51 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.32 (d, *J* = 16.0 Hz, 1H), 3.71 (s, 3H), 3.68 (s, 3H), 1.02 (s, 9H), 0.28 (s, 3H), 0.24 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.85, 159.34, 158.30, 148.13, 130.93, 130.18, 128.99, 122.85, 117.77, 113.35, 110.08, 69.07, 63.15, 55.16, 51.67, 26.07, 18.83, -3.55, -3.63; HRMS (ESI) calculated for C₂₅H₃₄NO₅Si [M+H] ⁺: 456.2201; found: 456.2186. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.7 mL/min, hexane:IPA = 97:3, t_r = 14.0, 16.2 min; 78% ee.



Methyl 3-(4-Bromophenyl)-5-(*tert*-butyldimethylsilyloxy)-2-phenyl-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11d). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.16-7.30 (comp, 4H), 7.07 (d, *J* = 8.4 Hz, 2H), 6.90-6.96 (comp, 3H), 5.51 (d, *J* = 1.6 Hz, 1H), 4.48 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.28 (d, *J* = 16.0 Hz, 1H), 3.64 (s, 3H), 0.97 (s, 9H), 0.24 (s, 3H), 0.20 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 165.23, 158.60, 147.38, 136.67, 131.05, 130.68, 128.65, 122.73, 121.70, 117.27, 108.96, 68.75, 62.89, 51.26, 25.58, 18.38, -3.99, -4.06; HRMS (ESI) calculated for C₂₄H₃₁BrNO₄Si [M+H] ⁺: 504.1200; found: 504.1201. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 1.0 mL/min, hexane:IPA = 97:3, t_r = 8.0, 11.3 min; 80% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(4-fluorophenyl)-2-phenyl-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11e). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 6.80-7.23 (comp, 9H), 5.53 (d, *J* = 1.6 Hz, 1H), 4.48 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.28 (d, *J* = 16.0 Hz, 1H), 3.64 (s, 3H), 0.98 (s, 9H), 0.24 (s, 3H), 0.20 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.27, 162.19 (d, J = 244.0 Hz), 158.35, 147.45, 133.32 (d, J = 3.2 Hz), 130.92 (d, J = 8.0 Hz), 128.56, 122.65, 117.32, 114.30 (d, J = 21.1 Hz), 109.22, 68.69, 62.80, 51.22, 25.57, 18.35, -4.02, -4.08; HRMS (ESI) calculated for C₂₄H₃₁FNO₄Si [M+H] ⁺: 444.2001; found: 444.1988. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.8 mL/min, hexane:IPA = 97:3, t_r = 10.0, 11.0 min; 77% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-2-phenyl-3-*m*-tolyl-3,6-dihydro-2*H*-1,2-oxazine-4carboxylate (11f). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 6.89-7.24 (comp, 9H), 5.55 (d, *J* = 1.6 Hz, 1H), 4.42 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.23 (d, *J* = 16.0 Hz, 1H), 3.63 (s, 3H), 2.22 (s, 3H), 0.95 (s, 9H), 0.21 (s, 3H), 0.16 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 165.38, 157.81, 147.48, 137.60, 136.97, 130.01, 128.54, 128.34, 127.36, 126.41, 122.43, 117.34, 109.25, 67.91, 62.58, 51.20, 25.58, 21.39, 18.35, -1.08, -1.17; HRMS (ESI) calculated for C₂₅H₃₄NO₄Si [M+H] ⁺: 440.2252; found: 440.2253. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.5 mL/min, hexane:IPA = 98:2, t_r = 12.4, 18.5 min; 90% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(3-chlorophenyl)-2-phenyl-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11g). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 6.90-7.24 (comp, 9H), 5.51 (d, *J* = 1.6 Hz, 1H), 4.44 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.25 (d, *J* = 16.0 Hz, 1H), 3.64 (s, 3H), 0.96 (s, 9H), 0.22 (s, 3H), 0.18 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 165.17, 158.69, 147.24, 139.75, 133.45, 129.30, 128.67, 128.63, 127.70, 122.77, 117.29, 108.67, 68.42, 62.78, 51.24, 25.55, 18.35, -4.03, -4.10; HRMS (ESI) calculated for $C_{24}H_{31}CINO_4Si$ [M+H]⁺: 460.1705; found: 460.1691. HPLC conditions for determination of the enantiomeric excess: OD-H column, 254 nm, 0.4 mL/min, hexane:IPA = 98:2, t_r = 11.8, 13.7 min; 85% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(naphthalen-2-yl)-2-phenyl-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11h). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.31-7.74 (comp, 7H), 7.17 (t, *J* = 7.6 Hz, 2H), 7.01 (d, *J* = 8.4 Hz, 2H), 6.88 (m, 1H), 5.75 (s, 1H), 4.50 (d, *J* = 16.0 Hz, 1H), 4.32 (d, *J* = 16.0 Hz, 1H), 3.61 (s, 3H), 0.98 (s, 9H), 0.26 (s, 3H), 0.21 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.32, 158.20, 147.50, 132.88, 132.83, 128.61, 128.51, 128.19, 127.53, 127.42, 127.08, 125.65,125.55, 122.53, 117.31, 109.37, 68.39, 63.01, 51.23, 25.55, 18.10, -1.01, -1.11; HRMS (ESI) calculated for C₂₈H₃₄NO₄Si [M+H]⁺: 476.2252; found: 476.2234. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 1.0 mL/min, hexane:IPA = 95:5, t_r = 7.6, 10.7 min; 80% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(furan-2-yl)-2-phenyl-3,6-dihydro-2*H*-1,2-oxazine-4-carboxylate (11i). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.20-7.30 (comp, 3H), 7.09 (d, *J* = 7.6 Hz, 2H), 7.00 (t, *J* = 7.6 Hz, 1H), 6.21 (m, 1H), 6.13 (d, *J* = 3.6 Hz, 1H), 5.72 (d, *J* = 1.6 Hz, 1H), 4.49 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.28 (d, *J* = 16.0 Hz, 1H), 3.73 (s, 3H), 1.00 (s, 9H), 0.26 (s, 3H), 0.23 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.50, 159.10, 152.27, 147.82, 142.38, 129.01, 123.07, 117.31, 110.38, 109.65, 107.95, 69.09, 57.25, 51.76, 26.03, 18.82, -3.57, -3.61; HRMS (ESI) calculated for C₂₂H₃₀NO₅Si [M+H] ⁺: 416.1888; found: 416.1863. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.5 mL/min, hexane:IPA = 97:3, t_r = 12.8, 13.7 min; 90% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-(furan-3-yl)-2-phenyl-3,6-dihydro-2*H*-1,2-oxazine-4-carboxylate (11j). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.21-7.38 (comp, 4H), 7.05 (d, J = 8.0 Hz, 2H), 7.00 (t, J = 8.0 Hz, 1H), 6.19 (m, 1H), 5.59 (d, J = 1.6 Hz, 1H), 4.53 (dd, J = 16.0 Hz, 1.6 Hz, 1H), 4.2 (d, J = 16.0 Hz, 1H), 3.74 (s, 3H), 1.00 (s, 9H), 0.26 (s, 3H), 0.23 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 166.01, 158.73, 147.95, 142.31, 141.79, 129.23, 122.70, 122.51, 117.01, 111.43, 111.00, 69.11, 55.43, 51.36, 26.02, 18.97, -3.59, -3.63; HRMS (ESI) calculated for C₂₂H₃₀NO₅Si [M+H] ⁺: 416.1888; found: 416.1876. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.5 mL/min, hexane:IPA = 97:3, t_r = 12.8, 15.2 min; 89% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-2-phenyl-3-(thiophen-2-yl)-3,6-dihydro-2*H*-1,2oxazine-4-carboxylate (11k). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.11-7.28 (comp, 3H), 7.05 (d, *J* = 8.0 Hz, 2H), 6.97 (t, *J* = 8.0 Hz, 1H), 6.78-6.83 (comp, 2H), 5.89 (d, *J* = 1.6 Hz, 1H), 4.57 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 4.35 (d, *J* = 16.0 Hz, 1H), 3.72 (s, 3H), 1.01 (s, 9H), 0.28 (s, 3H), 0.26 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 165.59, 158.93, 147.88, 140.58, 129.03, 127.75, 126.21, 125.80, 122.98, 117.27, 110.90, 69.75, 59.60, 51.71, 26.06, 18.81, -3.47, -3.49; HRMS (ESI) calculated for C₂₂H₃₀NO₄SSi [M+H] ⁺: 432.1659; found: 432.1644. HPLC conditions for determination of the enantiomeric excess: OD-H column, 254 nm, 0.5 mL/min, hexane:IPA = 97:3, t_r = 9.6, 10.5 min; 80% ee.



Methyl 5-(*tert*-Butyldimethylsilyloxy)-3-cyclohexyl-2-phenyl-3,6-dihydro-2*H*-1,2-oxazine-4carboxylate (111). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.23-7.27 (comp, 2H), 7.05 (d, J = 8.0 Hz, 2H), 6.91 (t, J = 7.2 Hz, 1H), 4.35 (d, J = 8.0 Hz, 1H), 4.03 (d, J = 16.0 Hz, 1H), 3.83 (d, J = 16.0 Hz, 1H), 3.76 (s, 3H), 2.08 (m, 1H), 1.84 (m, 1H), 1.69 (m, 2H), 1.61 (m, 2H), 1.00-1.25 (comp, 5H), 0.79 (s, 9H), -0.07 (s, 3H), -0.17 (s, 3H); ¹³C NMR (CDCl₃, 125 MHz): δ 166.91, 153.83, 147.28, 129.10, 121.79, 116.72, 109.83, 62.60, 59.59, 51.47, 42.61, 30.96, 29.93, 26.56, 26.42, 26.29, 25.42, 25.32, 18.08, -4.60, -4.65; HRMS (ESI) calculated for $C_{24}H_{38}NO_4Si$ [M+H]⁺: 432.2565; found: 432.2564. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 0.4 mL/min, hexane:IPA = 99:1, t_r = 9.7, 10.1 min; 77% ee.



Methyl 2-(*tert*-Butyldimethylsilyloxy)-3,6,7,11*b*-tetrahydro-[1,2]oxazino[3,2-*a*]isoquinoline-1-carboxylate (13). ¹H NMR (400 MHz, CDCl₃): δ (ppm) 7.07-7.24 (comp, 3H), 6.05 (d, *J* = 6.8 Hz, 1H), 5.08 (d, *J* = 1.6 Hz, 1H), 4.40 (dd, *J* = 16.0 Hz, 1.6 Hz, 1H), 3.95 (d, *J* = 16.0 Hz, 1H), 3.81 (s, 3H), 3.63 (m, 1H), 3.40 (m, 1H), 3.20 (m, 1H), 2.57 (m, 1H), 0.93 (s, 9H), 0.19 (s, 3H), 0.18 (s, 3H); ¹³C NMR (CDCl₃, 100 MHz): δ 167.25, 159.88, 136.61, 133.79, 128.73, 127.83, 126.81, 126.68, 110.45, 69.82, 58.37, 51.90, 51.24, 26.00, 23.81, 18.76, -3.38, -3.46; HRMS (ESI) calculated for C₂₀H₃₀NO₄Si [M+H] ⁺: 376.1939; found: 376.1930. HPLC conditions for determination of the enantiomeric excess: AD-H column, 254 nm, 1.0 mL/min, hexane:IPA = 97:3, t_r = 6.3, 8.4 min; 80% ee.

References

- (1) (a) Hashimoto, S.; Watanabe, N.; Sato, T.; Shiro, M.; Ikegami, S. *Tetrahedron lett.* 1993, 34, 5109. (b) Tsutsui, H.; Abe, T.; Nakamura, S.; Anada, M.; Hashimoto, S. *Chem. Pharm. Bull.* 2005, 53, 1366.
- (2) (b) (a) Liang, C.; Collet, F.; Robert-Peillard, F.; Müller, P.; Dodd, R. H.; Dauban, P. J. Am. Chem. Soc. 2008, 130, 343. (b) Müller, P.; Allenbach, Y.; Robert, E. Tetrahedron: Asymmetry 2003, 14, 779.
- (3) Reddy, R. P.; Lee, G. H.; Davies, H. M. L. Org. Lett. 2006, 8, 3437.
- (4) Davies, H. M. L.; Bruzinski, P. R.; Lake, D. H.; Kong, N.; Fall, M. J. J. Am. Chem. Soc. 1996, 118, 6897.
- (5) (a) Lo, M. M.-C.; Fu, G. C. J. Am. Chem. Soc. 2002, 124, 4572. (b) Murahashi, S.-I.; Mitsui, H.; Shiota, T.; Tsuda, T.; Watanabe, S. J. Org. Chem. 1990, 55, 1736. (c) West, P. R.; Davis, G. C. J. Org. Chem. 1989, 54, 5176.
- (6) Davies, H. M. L.; Ahmed, G.; Churchill, M. R. J. Am. Chem. Soc. 1996, 118, 10774.





S10





































































